KOSDAQBiotech & Pharma229000

Gencurix

₩1,957 0.00%2026-11-18 close
Market Cap
₩47.3B
Turnover
₩0
Volume
0 shares
Shares out.
24.2M
PER
—
PBR
—
EPS
-₩334
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue growth with narrowing losses: Gencurix's earnings structure

Gencurix's revenue has grown for three straight years through 2025, but operating losses have continued for four consecutive years, and funding plans and overseas revenue realization are the next points to watch.

  1. 1

    Revenue rose from KRW 2.56 billion in 2022 to KRW 7.55 billion in 2025, with 2025 up 47.0% year on year.

  2. 2

    The operating margin improved from -430.1% in 2022 to -87.0% in 2025, but an operating loss of KRW 6.57 billion in 2025 means the loss structure remains.

  3. 3

    Third-quarter 2026 revenue was KRW 2.4 billion, up 38.7% year on year, and the operating loss was KRW 820 million, narrower than KRW 1.63 billion a year earlier.

  4. 4

    A KRW 500 million convertible bond issued in September 2026 and merger shares listed on November 5, 2026 have changed the capital structure.

  5. 5

    The debt ratio fell to 96.1% at the end of 2025 from 556.4% in 2022, yet operating cash flow remained negative at KRW 6.24 billion in 2025.

02

Business structure

Gencurix is a specialist in cancer molecular diagnostics centered on digital PCR (ddPCR). Its flagship product is the breast cancer prognostic test Jinswell BCT, supplemented by the companion diagnostic Droplex, a digital PCR-based test.

Its Jinswell BCT prescriptions at large general hospitals rose 130% year on year in 2024, according to the company. Overseas revenue is expected to appear for the first time in 2026.

Gencurix has supplied cancer diagnostic products to Bio-Rad in 32 European countries and obtained CE-IVDR certification for several companion diagnostics in January 2026. Partnerships include Roche, QIAGEN and Hitachi High-Tech, and the company is pursuing southern China through Hainan with a local partner.

In competition, next-generation sequencing (NGS) is seen as costly and slow for routine clinical use, positioning ddPCR as a complementary tool. The company also holds a government R&D project with a total budget of KRW 29.38 billion running from April 2026 to December 2032. The merger with a private IVD developer added liquid biopsy know-how and expanded its product pipeline.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.7B-₩1.6B−94.4%
2025Q4₩2.1B-₩2.1B−97.3%
2026Q1₩2.1B-₩1B−48.0%
2026Q2₩3B-₩700M−23.5%
2026Q3₩2.4B-₩800M−34.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.6B-₩11B-₩24.6B−430.1%−379.9%556.4%
2023₩2.6B-₩11.2B-₩19.3B−429.1%−139.8%179.1%
2024₩5.1B-₩8.5B-₩4.1B−166.1%−27.8%101.7%
2025₩7.5B-₩6.6B-₩7.4B−87.0%−45.1%96.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Based on reported results, annual revenue was KRW 2.56 billion in 2022, KRW 2.6 billion in 2023 (up 1.6% year on year), KRW 5.13 billion in 2024 (up 97.4%), and KRW 7.55 billion in 2025 (up 47.0%), rising for three consecutive years from 2023 to 2025. 2025 was the year with the highest revenue among 2022-2025.

Operating losses were KRW 11.0 billion in 2022, KRW 11.2 billion in 2023, KRW 8.53 billion in 2024, and KRW 6.57 billion in 2025, so the company posted losses for four consecutive years from 2022 to 2025, although the loss narrowed in 2024 and 2025. The operating margin improved from -430.1% in 2022 to -87.0% in 2025.

In the preliminary announcement on January 16, 2026, the 2025 operating loss was reported as KRW 6.1 billion, but this came with the caveat that it was a preliminary figure released before the books were finalized, that some profit and loss items reflected estimates, and that it could change; the confirmed figure in the periodic report is KRW 6.57 billion.

Net loss attributable to controlling shareholders widened from KRW 4.15 billion in 2024 to KRW 7.39 billion in 2025, and the company explained that non-operating income decreased, which reduced income from continuing operations before income tax and net income.

The debt ratio fell from 556.4% in 2022 to 96.1% in 2025, and the cash outflow from operating activities shrank from -KRW 10.5 billion in 2022 to -KRW 6.24 billion in 2025.

Quarterly revenue was KRW 1.73 billion in Q3 2025, KRW 2.11 billion in Q4 2025 (up 22.2% quarter on quarter), KRW 2.1 billion in Q1 2026, KRW 2.99 billion in Q2 2026 (up 42.3%), and KRW 2.4 billion in Q3 2026 (down 19.8%), peaking in Q2 2026.

Quarterly operating losses narrowed from KRW 1.63 billion in Q3 2025 and KRW 2.05 billion in Q4 2025 to KRW 1.01 billion in Q1 2026, KRW 0.7 billion in Q2 2026, and KRW 0.82 billion in Q3 2026, with the Q3 loss widening slightly from Q2.

The company has posted losses for five consecutive quarters, from Q3 2025 to Q3 2026. As for the reasons the loss narrowed, there is an explanation that the loss structure improved as the easing of fixed-cost burden from revenue growth combined with business efficiency measures.

In addition, government subsidies from an expanded number of government R&D projects helped ease the R&D expense burden, and cumulative ordinary R&D expenses for the first half were about KRW 0.3 billion lower than in the same period a year earlier.

The combined net loss attributable to controlling shareholders over the latest four quarters (Q4 2025 to Q3 2026) is KRW 7.03 billion.

05

Industry analysis

According to a securities firm's corporate monitoring assessment as of August 2025, demand for breast cancer prognostic and companion diagnostics is forecast to grow at a double-digit rate owing to demographics, policy, and the paradigm shift toward precision medicine, and demand for targeted therapies, prognostic diagnostics, and companion diagnostics is rising as the need for personalized care grows.

The domestic market appears to be at a stage where prescriptions at large hospitals are increasing, and whether overseas revenue is added is the variable for the next growth phase.

On the technology side, in the DropPlex-based ESR1 and PIK3CA detection results the company announced in April 2026, ESR1 mutations were detected at a sensitivity of about 0.1%, and the results showed 96.8% concordance with NGS results on 32 breast cancer samples.

The company presented these results as its own performance data, and the scope of independent validation results confirmed so far is not broad. In a September 2026 conference presentation, bronchial fluid showed higher concordance with tissue biopsy results than plasma in 53 lung cancer patients.

In the competitive landscape, NGS is described as complementary rather than a substitute, and the company's research center head explained that ddPCR-based testing can have high practicality as a complementary tool that enables rapid, repeatable biomarker assessment in clinical practice rather than replacing NGS.

However, whether liquid biopsy-based tests become standard tests at the point of prescription depends on the academic evidence and the speed of prescription adoption.

A supply agreement with a global diagnostics company can serve as a distribution channel while also acting as a variable for the pace of expanding the company's own brand.

06

Outlook

The company expects overseas revenue to occur for the first time in 2026, so how overseas revenue is recorded in quarterly results is the point to check.

In Europe, the company is pursuing European CE-IVDR certification for additional products, and it is worth watching whether expanded certification leads to more orders.

The national project involves developing a next-generation digital PCR integrated platform for early screening of major cancers, and the development schedule runs through 2032.

On the research side, the company said it plans to expand its technology scope from therapeutic target analysis using multiplex digital PCR to WGS-based MRD research, building a cancer precision diagnostics portfolio that extends from diagnosis to treatment selection and post-treatment monitoring.

On funding, as of August 2026 the company is in discussions with a strategic investor (SI) on funding options, and its position is that it will announce details through the relevant procedures once specifics are finalized.

In September 2026, it issued KRW 500 million of convertible bonds to KB Securities as the bond subscriber; the entire KRW 500 million raised is to be used for operating funds such as labor and material costs, and all of it is planned to be spent within 2026.

The 742,456 new merger shares were subject to mandatory holding in full, covering all 742,456 new merger shares. The next point to check is the 2026 annual report and full-year results, and if preliminary results come out first as in 2025, that could be around mid-January 2027.

07

Valuation

PER
—
PBR
—
ROE
-63.8%
EPS
-₩334
BPS
—
Dividend per share
₩0

PER, an earnings-based multiple, cannot be calculated because net losses have continued over the latest four quarters. This is a phase in which net assets, capital structure, and business events are considered together instead of earnings.

At the end of 2025, total equity was KRW 16.4 billion, and equity attributable to controlling shareholders was the same KRW 16.4 billion, while total liabilities were KRW 15.7 billion, for a debt ratio of 96.1%.

Because net assets tend to move downward during periods of continued losses, the change in capital, the denominator, should also be watched when interpreting the price-to-book ratio (PBR). No dividend is being paid, so comparing the dividend yield with the industry has limited meaning.

The conversion price of the convertible bonds is KRW 1,919 per share, and the minimum adjusted price if the market price falls is set at KRW 1,344, so the number of shares issued upon conversion can vary with the share price level.

Since 742,456 new merger shares were listed on November 5, 2026, share-count-based metrics should also reflect this quantity. Valuation is a structure with a wide range of interpretation depending on business events such as overseas contracts, certification, and funding rather than on earnings multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Three years of revenue growth

Revenue grew for three straight years from 2023 through 2025, reaching KRW 7.55 billion in 2025 versus KRW 2.56 billion in 2022. Third-quarter 2026 revenue rose 38.7% year on year, with Jinswell BCT prescriptions as the domestic growth base.

Overseas certification and partnerships

Following CE-IVDR certification in January 2026, additional orders followed in May and July. Partnerships with Roche, QIAGEN and Hitachi High-Tech are ongoing, and southern China entry is in discussion, so overseas revenue would broaden the sales mix if realized as the company expects.

Narrowing loss trend

The quarterly operating loss narrowed from KRW 1.63 billion in the third quarter of 2025 to KRW 820 million in the third quarter of 2026, which the company attributes to lower fixed-cost burden and government R&D subsidies.

09

Bear factors

Continuing operating losses and cash outflow

Operating losses persisted for four consecutive years through 2025, with a KRW 6.57 billion loss in 2025. Operating cash flow was negative at KRW 6.24 billion in 2025, and losses have continued for five consecutive quarters through the third quarter of 2026, with no turn to profit yet in view.

Funding needs and dilution risk

A KRW 500 million convertible bond was issued in September 2026 at a conversion price of KRW 1,919, with a floor adjustment price of KRW 1,344. Merger shares of 742,456 were listed, and funding talks with a strategic investor are ongoing, so a larger share count could slow per-share improvement.

Whether overseas revenue materializes

The company expected overseas revenue to begin in 2026, but third-quarter 2026 revenue fell 19.8% from the prior quarter after peaking in the second quarter, so the timing of overseas revenue recognition is key.

10

Risk factors

Financial and liquidity risk

Operating losses continue, and operating cash outflow was KRW 6.24 billion in 2025. The CEO acknowledged market concerns over liquidity, and funding options are under review, so delays could affect R&D and certification timing.

Product and revenue concentration risk

Revenue depends on sales growth of Jinswell BCT and digital PCR-based companion diagnostics. A slowdown in domestic prescriptions or delays in overseas supply contracts could lower growth, while product diversification is still at an early stage.

Government support and regulatory risk

Government R&D subsidies have helped reduce the burden of R&D spending. Changes in project scope or subsidy terms could alter the cost structure, and overseas sales depend on meeting certification standards such as CE-IVDR.

11

What to watch next

  1. Timing undetermined (when financing is confirmed)

    Whether funding talks with a strategic investor are finalized, along with the size and structure, is the next point to check, since it would change share count and capital structure.

  2. Around mid-January 2027

    The preliminary 2026 annual results, which for 2025 were released on January 16, 2026. Whether revenue growth continues and how much the operating loss narrows are the key checks.

  3. By March 31, 2027

    The deadline for the 2026 annual report, which will confirm profit and loss, cash flow and overseas revenue in disclosed figures.

  4. By May 15, 2027

    The deadline for the first-quarter 2027 report, which will show whether revenue decline continues and whether overseas sales appear.

  5. September 11, 2027

    The start of the conversion period for the convertible bond issued in September 2026, which runs until August 10, 2029, and determines potential dilution.

12

Overall view

Gencurix grew revenue from KRW 2.56 billion in 2022 to KRW 7.55 billion in 2025, with three straight years of growth from 2023. The operating loss narrowed to KRW 6.57 billion in 2025, but the company has not yet escaped four consecutive years of losses.

Third-quarter 2026 revenue of KRW 2.4 billion and an operating loss of KRW 820 million show growth and a narrower loss year on year. Supporting factors include domestic Jinswell BCT prescription growth, European CE-IVDR certification with follow-on orders, and global partnerships.

Negative factors include continued operating cash outflow, a higher share count from the convertible bond and merger shares, and the quarter-on-quarter revenue decline in the third quarter of 2026.

The next points to check are the outcome of funding talks, the 2026 preliminary annual results, and the overseas revenue figure in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. news.nate.com
  2. news.nate.com
  3. thebionews.net
  4. hankyung.com
  5. comp.wisereport.co.kr
  6. ebn.co.kr
  7. newspim.com
  8. thebionews.net
  9. medifonews.com
  10. topstarnews.net
  11. m.news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. kr.investing.com
  16. etoday.co.kr
  17. etoday.co.kr
  18. newspim.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis